Evan Hy Einstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Evan Hy Einstein has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Andrew F. Leuchter
4 shared publications- Aaron Slan
TMS Clinical and Research Service, Neuromodulation Division, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, USA
3 shared publications David E. Krantz
3 shared publicationsHamza Khilji
Department of Neurological Surgery, Lenox Hill Hospital/Donald and Barbara Zucker School of Medicine at Hofstra, New York, USA
3 shared publicationsHanadi A. Oughli
3 shared publicationsJustin W. Silverstein
Department of Neurology, Lenox Hill Hospital/Donald and Barbara Zucker School of Medicine at Hofstra, New York, USA
3 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by Hogrefe Publishing Group in Sports Psychiatry
- Vol. 5 (2) , 71-73
Hidden talent on the bench: the underexplored role of TMS in sports psychiatry
- 1 June 2026
- Published by Hogrefe Publishing Group in Sports Psychiatry
- Vol. 5 (2) , 71-73
Open AccessHidden talent on the bench: the underexplored role of TMS in sports psychiatry
- Open Access
- 14 February 2026
- Published by Elsevier in Transcranial Magnetic Stimulation
- Vol. 6
Trajectories of patient-rated baseline-severe depressive symptoms during repetitive transcranial magnetic stimulation (rTMS) for major depressive disorder
- 14 February 2026
- Published by Elsevier in Transcranial Magnetic Stimulation
- Vol. 6
Open AccessTrajectories of patient-rated baseline-severe depressive symptoms during repetitive transcranial magnetic stimulation (rTMS) for major depressive disorder
- Open Access
- 7 January 2026
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 51 (5) , 813-821
Differential neural responses to rhythmic and patterned TMS protocols: Insights from EEG spectral analysis
Repetitive Transcranial Magnetic Stimulation (rTMS) engages brain networks for the treatment of Major Depressive Disorder (MDD), using either rhythmic (e.g., 10 Hz) or patterned (e.g., intermittent Theta Burst, or iTBS) stimulation protocols. The distinct effects of these protocols on brain function are not well understood. Sixteen subjects with MDD underwent a TMS–electroencephalography (TMS–EEG) “interrogation” paradigm, in which a broad range of rhythmic and patterned stimulation frequencies were administered in a randomized order to the left dorsolateral prefrontal cortex (L-DLPFC). rTMS-induced changes in oscillatory activity and effective connectivity to the DLPFC were examined at each frequency. Linear mixed-effects models revealed widespread changes in power and connectivity, with magnitude and regional distribution of change dependent upon both protocol and frequency of stimulation. Increases in beta band power were most prominent with patterned stimulation, while rhythmic stimulation increased both alpha and beta power at stimulation frequencies greater than 7 Hz ( p < 0.05). Source localization showed that patterned and rhythmic stimulation elicited activation in distinct subregions of the cingulate. Rhythmic and patterned stimulation also had distinct effects on connectivity: notably, only rhythmic stimulation increased connectivity with regions near the stimulation site, while only patterned stimulation decreased connectivity to the left precuneus. Both protocols increased the effective connectivity to the orbitofrontal cortex in the theta and beta response bands ( p < 0.05). These results indicate that rhythmic and patterned rTMS engage distinct brain regions in a protocol- and frequency-dependent manner. Future studies should examine how these mechanistic differences may relate to clinical outcomes.
- 7 January 2026
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 51 (5) , 813-821
Open AccessDifferential neural responses to rhythmic and patterned TMS protocols: Insights from EEG spectral analysis
Repetitive Transcranial Magnetic Stimulation (rTMS) engages brain networks for the treatment of Major Depressive Disorder (MDD), using either rhythmic (e.g., 10 Hz) or patterned (e.g., intermittent Theta Burst, or iTBS) stimulation protocols. The distinct effects of these protocols on brain function are not well understood. Sixteen subjects with MDD underwent a TMS–electroencephalography (TMS–EEG) “interrogation” paradigm, in which a broad range of rhythmic and patterned stimulation frequencies were administered in a randomized order to the left dorsolateral prefrontal cortex (L-DLPFC). rTMS-induced changes in oscillatory activity and effective connectivity to the DLPFC were examined at each frequency. Linear mixed-effects models revealed widespread changes in power and connectivity, with magnitude and regional distribution of change dependent upon both protocol and frequency of stimulation. Increases in beta band power were most prominent with patterned stimulation, while rhythmic stimulation increased both alpha and beta power at stimulation frequencies greater than 7 Hz ( p < 0.05). Source localization showed that patterned and rhythmic stimulation elicited activation in distinct subregions of the cingulate. Rhythmic and patterned stimulation also had distinct effects on connectivity: notably, only rhythmic stimulation increased connectivity with regions near the stimulation site, while only patterned stimulation decreased connectivity to the left precuneus. Both protocols increased the effective connectivity to the orbitofrontal cortex in the theta and beta response bands ( p < 0.05). These results indicate that rhythmic and patterned rTMS engage distinct brain regions in a protocol- and frequency-dependent manner. Future studies should examine how these mechanistic differences may relate to clinical outcomes.
- Open Access
- 25 December 2024
- Published by Elsevier in Transcranial Magnetic Stimulation
- Vol. 3
The neuromodulation revolution: Planning for the future of brain stimulation in psychiatry
- 25 December 2024
- Published by Elsevier in Transcranial Magnetic Stimulation
- Vol. 3
Open AccessThe neuromodulation revolution: Planning for the future of brain stimulation in psychiatry
- 28 June 2022
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 159 (2) , 369-375
Stimulated Raman histology facilitates accurate diagnosis in neurosurgical patients: a one-to-one noninferiority study
Objective Stimulated Raman histology (SRH) offers efficient and accurate intraoperative neuropathological tissue analysis without procedural alteration to the diagnostic specimen. However, there are limited data demonstrating one-to-one tissue comparisons between SRH and traditional frozen sectioning. This study explores the non-inferiority of SRH as compared to frozen section on the same piece of tissue in neurosurgical patients. Methods Tissue was collected over a 1-month period from 18 patients who underwent resection of central nervous system lesions. SRH and frozen section analyses were compared for diagnostic capabilities as well as assessed for quality and condition of tissue via a survey completed by pathologists. Results SRH was sufficient for diagnosis in 78% of specimens as compared to 94% of specimens by frozen section of the same specimen. A Fisher’s exact test determined there was no significant difference in diagnostic capability between the two groups. Additionally, both quality of SRH and condition of tissue after SRH were deemed to be non-inferior to frozen section. Conclusions This study provides further evidence for the non-inferiority of SRH techniques. It is also the first study to demonstrate SRH accuracy using one-to-one tissue analysis in neuropathological specimens.
- 28 June 2022
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 159 (2) , 369-375
Stimulated Raman histology facilitates accurate diagnosis in neurosurgical patients: a one-to-one noninferiority study
Objective Stimulated Raman histology (SRH) offers efficient and accurate intraoperative neuropathological tissue analysis without procedural alteration to the diagnostic specimen. However, there are limited data demonstrating one-to-one tissue comparisons between SRH and traditional frozen sectioning. This study explores the non-inferiority of SRH as compared to frozen section on the same piece of tissue in neurosurgical patients. Methods Tissue was collected over a 1-month period from 18 patients who underwent resection of central nervous system lesions. SRH and frozen section analyses were compared for diagnostic capabilities as well as assessed for quality and condition of tissue via a survey completed by pathologists. Results SRH was sufficient for diagnosis in 78% of specimens as compared to 94% of specimens by frozen section of the same specimen. A Fisher’s exact test determined there was no significant difference in diagnostic capability between the two groups. Additionally, both quality of SRH and condition of tissue after SRH were deemed to be non-inferior to frozen section. Conclusions This study provides further evidence for the non-inferiority of SRH techniques. It is also the first study to demonstrate SRH accuracy using one-to-one tissue analysis in neuropathological specimens.
- 19 April 2022
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 157 (3) , 445
Correction to: Transcranial magnetic stimulation for post-operative neurorehabilitation in neuro-oncology: a review of the literature and future directions
- 19 April 2022
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 157 (3) , 445
Correction to: Transcranial magnetic stimulation for post-operative neurorehabilitation in neuro-oncology: a review of the literature and future directions
- 25 March 2022
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 157 (3) , 435-443
Transcranial magnetic stimulation for post-operative neurorehabilitation in neuro-oncology: a review of the literature and future directions
Introduction Transcranial magnetic stimulation (TMS) is a neuromodulation technology capable of targeted stimulation and inhibition of cortical areas. Repetitive TMS (rTMS) has demonstrated efficacy in the treatment of several neuropsychiatric disorders, and novel uses of rTMS for neurorehabilitation in patients with acute and chronic neurologic deficits are being investigated. However, studies to date have primarily focused on neurorehabilitation in stroke patients, with little data supporting its use for neurorehabilitation in brain tumor patients. Methods We performed a review of the current available literature regarding uses of rTMS for neurorehabilitation in post-operative neuro-oncologic patients. Results Data have demonstrated that rTMS is safe in the post-operative neuro-oncologic patient population, with minimal adverse effects and no documented seizures. The current evidence also demonstrates potential effectiveness in terms of neurorehabilitation of motor and language deficits. Conclusions Although data are overall limited, both safety and effectiveness have been demonstrated for the use of rTMS for neurorehabilitation in the neuro-oncologic population. More randomized controlled trials and specific comparisons of contralateral versus ipsilateral rTMS protocols should be explored. Further work may also focus on individualized, patient-specific TMS treatment protocols for optimal functional recovery.
- 25 March 2022
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 157 (3) , 435-443
Transcranial magnetic stimulation for post-operative neurorehabilitation in neuro-oncology: a review of the literature and future directions
Introduction Transcranial magnetic stimulation (TMS) is a neuromodulation technology capable of targeted stimulation and inhibition of cortical areas. Repetitive TMS (rTMS) has demonstrated efficacy in the treatment of several neuropsychiatric disorders, and novel uses of rTMS for neurorehabilitation in patients with acute and chronic neurologic deficits are being investigated. However, studies to date have primarily focused on neurorehabilitation in stroke patients, with little data supporting its use for neurorehabilitation in brain tumor patients. Methods We performed a review of the current available literature regarding uses of rTMS for neurorehabilitation in post-operative neuro-oncologic patients. Results Data have demonstrated that rTMS is safe in the post-operative neuro-oncologic patient population, with minimal adverse effects and no documented seizures. The current evidence also demonstrates potential effectiveness in terms of neurorehabilitation of motor and language deficits. Conclusions Although data are overall limited, both safety and effectiveness have been demonstrated for the use of rTMS for neurorehabilitation in the neuro-oncologic population. More randomized controlled trials and specific comparisons of contralateral versus ipsilateral rTMS protocols should be explored. Further work may also focus on individualized, patient-specific TMS treatment protocols for optimal functional recovery.
- Open Access
- 7 February 2022
- Published by Springer Nature in Research Square
Transcranial Magnetic Stimulation for Post-Operative Neurorehabilitation in Neuro-Oncology: A Review of the Literature and Future Directions
Introduction: Transcranial magnetic stimulation (TMS) is a neuromodulation technology capable of targeted stimulation and inhibition of cortical areas. Repetitive TMS (rTMS) has demonstrated efficacy in the treatment of several neuropsychiatric disorders, and novel uses of rTMS for neurorehabilitation in patients with acute and chronic neurologic deficits are being investigated. However, studies to date have primarily focused on neurorehabilitation in stroke patients, with little data supporting its use for neurorehabilitation in brain tumor patients. Methods: We performed a review of the current available literature regarding uses of rTMS for neurorehabilitation in post-operative neuro-oncologic patients. Results: Data have demonstrated that rTMS is safe in the post-operative neuro-oncologic patient population, with minimal adverse effects and no documented seizures. The current evidence also demonstrates potential effectiveness in terms of neurorehabilitation of motor and language deficits. Conclusions: Although data are overall limited, both safety and effectiveness have been demonstrated for the use of rTMS for neurorehabilitation in the neuro-oncologic population. More randomized controlled trials and specific comparisons of contralateral versus ipsilateral rTMS protocols should be explored. Further work may also focus on individualized, patient-specific TMS treatment protocols for optimal functional recovery.
- 7 February 2022
- Published by Springer Nature in Research Square
Open AccessTranscranial Magnetic Stimulation for Post-Operative Neurorehabilitation in Neuro-Oncology: A Review of the Literature and Future Directions
Introduction: Transcranial magnetic stimulation (TMS) is a neuromodulation technology capable of targeted stimulation and inhibition of cortical areas. Repetitive TMS (rTMS) has demonstrated efficacy in the treatment of several neuropsychiatric disorders, and novel uses of rTMS for neurorehabilitation in patients with acute and chronic neurologic deficits are being investigated. However, studies to date have primarily focused on neurorehabilitation in stroke patients, with little data supporting its use for neurorehabilitation in brain tumor patients. Methods: We performed a review of the current available literature regarding uses of rTMS for neurorehabilitation in post-operative neuro-oncologic patients. Results: Data have demonstrated that rTMS is safe in the post-operative neuro-oncologic patient population, with minimal adverse effects and no documented seizures. The current evidence also demonstrates potential effectiveness in terms of neurorehabilitation of motor and language deficits. Conclusions: Although data are overall limited, both safety and effectiveness have been demonstrated for the use of rTMS for neurorehabilitation in the neuro-oncologic population. More randomized controlled trials and specific comparisons of contralateral versus ipsilateral rTMS protocols should be explored. Further work may also focus on individualized, patient-specific TMS treatment protocols for optimal functional recovery.